Davis MR - Search Results

1

Asbestos fibres inhibit the in vitro activity of lymphokine-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma.

Manning LS, Davis MR, Robinson BW. Manning LS, et al. Among authors: davis mr. Clin Exp Immunol. 1991 Jan;83(1):85-91. doi: 10.1111/j.1365-2249.1991.tb05593.x. Clin Exp Immunol. 1991. PMID: 1846329 Free PMC article.

2

Establishment of a murine model of malignant mesothelioma.

Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Davis MR, et al. Int J Cancer. 1992 Dec 2;52(6):881-6. doi: 10.1002/ijc.2910520609. Int J Cancer. 1992. PMID: 1459729

3

Establishment and characterization of five human malignant mesothelioma cell lines derived from pleural effusions.

Manning LS, Whitaker D, Murch AR, Garlepp MJ, Davis MR, Musk AW, Robinson BW. Manning LS, et al. Among authors: davis mr. Int J Cancer. 1991 Jan 21;47(2):285-90. doi: 10.1002/ijc.2910470219. Int J Cancer. 1991. PMID: 1703129

4

HLA antigen expression and malignant mesothelioma.

Christmas TI, Manning LS, Davis MR, Robinson BW, Garlepp MJ. Christmas TI, et al. Among authors: davis mr. Am J Respir Cell Mol Biol. 1991 Sep;5(3):213-20. doi: 10.1165/ajrcmb/5.3.213. Am J Respir Cell Mol Biol. 1991. PMID: 1910807

5

Chemosensitivity and cytokine sensitivity of malignant mesothelioma.

Bowman RV, Manning LS, Davis MR, Robinson BW. Bowman RV, et al. Among authors: davis mr. Cancer Chemother Pharmacol. 1991;28(6):420-6. doi: 10.1007/BF00685817. Cancer Chemother Pharmacol. 1991. PMID: 1934246

6

Capacity of tumor necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma.

Bowman RV, Manning LS, Davis MR, Robinson BW. Bowman RV, et al. Among authors: davis mr. Clin Immunol Immunopathol. 1991 Jan;58(1):80-91. doi: 10.1016/0090-1229(91)90150-9. Clin Immunol Immunopathol. 1991. PMID: 1983971

7

Interaction between dactinomycin and tumor necrosis factor in mesothelioma. Cachexia without oncolysis.

Bowman RV, Whitaker D, Manning LS, Davis MR, Robinson BW. Bowman RV, et al. Among authors: davis mr. Cancer. 1991 May 15;67(10):2495-500. doi: 10.1002/1097-0142(19910515)67:10<2495::aid-cncr2820671018>3.0.co;2-8. Cancer. 1991. PMID: 2015549

8

Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma.

Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BW. Manning LS, et al. Among authors: davis mr. Clin Immunol Immunopathol. 1989 Oct;53(1):68-77. doi: 10.1016/0090-1229(89)90102-5. Clin Immunol Immunopathol. 1989. PMID: 2788546

9

Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.

Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BW. Bielefeldt-Ohmann H, et al. Among authors: davis mr. Cancer Immunol Immunother. 1994 Dec;39(6):347-59. doi: 10.1007/BF01534421. Cancer Immunol Immunother. 1994. PMID: 8001022 Free PMC article.

10

Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.

Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, Engelter ST, Indredavik B, Jatužis D, Karelis G, Kõrv J, Lundström E, Petersson J, Putaala J, Søyland MH, Tveiten A, Bivard A, Johnsen SH, Mazya MV, Werring DJ, Wu TY, De Marchis GM, Robinson TG, Mathiesen EB; TWIST Investigators. Roaldsen MB, et al. Lancet Neurol. 2023 Feb;22(2):117-126. doi: 10.1016/S1474-4422(22)00484-7. Epub 2022 Dec 19. Lancet Neurol. 2023. PMID: 36549308 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

286 results

Search Page

Filters